Dr Renuka Iyer Appointed Chief Medical Officer of NCCN

Dr Renuka Iyer has been appointed as the new Chief Medical Officer (CMO) of the National Comprehensive Cancer Network (NCCN). Her appointment, effective from 26 February 2026, marks a major leadership transition at the organisation known globally for its authoritative cancer treatment guidelines. Dr Iyer is a distinguished oncologist with over 20 years of experience in academic medicine, research, and clinical practice. She is renowned for her work in gastrointestinal cancers, especially rare tumours, and has contributed significantly to oncology guidelines and education.

Background on NCCN

The National Comprehensive Cancer Network (NCCN) is a not-for-profit alliance of leading cancer centers in the United States. It is globally recognised for publishing and maintaining 90 clinical practice guidelines, widely used by healthcare providers to ensure evidence-based, high-quality cancer care.

NCCN also contributes to,

• Educational programmes for healthcare professionals
• Global collaborations to enhance cancer care access
• Policy advocacy and drug compendia for clinical use

NCCN’s guidelines are updated at least annually, reflecting the latest research, innovations, and clinical standards.

Who is Dr Renuka Iyer?

Dr Renuka Iyer currently serves as the Section Chief of Gastrointestinal Oncology and Professor of Oncology at Roswell Park Comprehensive Cancer Center in New York. She also oversees the medical oncology care network at the institution.

Her educational journey includes,

• Medical training from Grant Medical College, India
• Residency at Cornell University
• Oncology fellowship at Roswell Park

She is board certified in internal medicine and medical oncology, and has a proven track record in clinical care, research, and medical leadership.

Contributions to Oncology and Research

Dr Iyer is known for her work in immunotherapy, biomarker research, and studies on quality of life in cancer patients. Her contributions span,

• Publishing extensively in peer-reviewed journals
• Leading research on rare gastrointestinal cancers
• Serving on professional guideline panels, including NCCN committees
• Actively promoting evidence-based clinical practice

She has played a key role on the NCCN Guidelines Steering Committee since 2023, influencing how cancer care pathways are designed and updated.

Her Role as NCCN Chief Medical Officer

As the new CMO of NCCN, Dr Iyer will lead a range of critical functions, including,

• Overseeing the development and updates of NCCN Clinical Practice Guidelines
• Guiding point-of-care resources such as the NCCN Compendia
• Leading continuing education programmes for clinicians worldwide
• Supporting global partnerships and policy-driven cancer initiatives
• Contributing to NCCN’s strategic planning and research frameworks

She will also help drive the editorial direction of NCCN’s journal and work on expanding the network’s global footprint in cancer education and care standards.

Significance of the Appointment

Dr Iyer’s appointment comes at a time when NCCN is,

• Expanding its educational and policy outreach globally
• Promoting equity in cancer care through international partnerships
• Innovating in areas like digital guideline delivery and decision-support tools

Her deep clinical expertise, research background, and leadership record are expected to strengthen NCCN’s mission to standardise cancer care globally and improve outcomes across diverse populations.

Static Facts

• Name: Dr Renuka Iyer
• New Role: Chief Medical Officer, NCCN
• Effective Date: 26 February 2026
• Current Position: Section Chief of Gastrointestinal Oncology, Roswell Park
• Educational Background: Grant Medical College, Cornell University, Roswell Park
• NCCN Guidelines: 90 clinical pathways updated regularly